Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

A Northeastern-Southwestern deal
November 2019
SHARING OPTIONS:

HOPKINTON, Mass.—Spring Bank Pharmaceuticals Inc. and the University of Texas Southwestern (UTSW) Medical School have inked a research agreement to assess the former’s novel small-molecule STimulator of INterferon Gene (STING) antagonist compounds. The STING compounds block aberrant STING-dependent signaling, and are being developed for use in treating autoimmune diseases, including some interferonopathies. Financial terms were not dislcosed.
 
“There is a significant unmet medical need for the treatment of diseases where the cGAS-STING pathway is dysregulated. We are excited to collaborate with Spring Bank in the evaluation of these novel STING antagonist compounds in mouse models of autoimmune and inflammatory diseases,” stated Dr. Nan Yan, associate professor and Rita C. and William P. Clements, Jr. Scholar in Medical Research at the UTSW Medical Center. Yan will serve as principal investigator for this agreement.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.